<DOC>
	<DOCNO>NCT02932462</DOCNO>
	<brief_summary>A Randomized Double-Blind , Vehicle-Controlled , Parallel Design , Multiple-Site , Phase III Clinical Study</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Topical Product Patients With Mild Severe Scalp Psoriasis</brief_title>
	<detailed_description>This randomize , double-blind , vehicle-controlled , parallel-group multiple-site study design evaluate therapeutic efficacy safety investigational product , DSXS 1535 product , treatment mild severe scalp psoriasis</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patients clinical diagnosis mild severe plaque psoriasis scalp , define Investigator 's Global Assessment ( IGA ) score least 2 baseline/randomization Patients whose scalp psoriasis necessitates systemic concomitant topical therapy study ( concomitant treatment body psoriasis counter topical product include emollient , allow ) . Patient scalp skin condition would interfere diagnosis assessment plaque psoriasis scalp ( e.g. , seborrheic dermatitis , eczema , cutaneous Tcell lymphoma , form psoriasis include guttate , inverse , pustular erythrodermic psoriasis ) Presence pigmentation , extensive scarring , pigmented lesion , sunburn treatment area could interfere rating efficacy parameter , include plan extensive exposure sunlight study . History psoriasis unresponsive topical treatment . Current immunosuppression history organ transplant . Patients history current diagnosis glaucoma . Patients surgery eye eyelid within 1 month baseline plan eye eyelid surgery study . Patients active infection ( include limit bacterial , fungal viral infection ) and/or open wound entire head neck area .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>